Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5-deoxy-5-fluorocytidine, 5-deoxy-5-fluorouridine, and 5-fluorouracil was written by Sekido, Masae;Fujita, Ken-ichi;Kubota, Yutaro;Ishida, Hiroo;Takahashi, Takehiro;Ohkuma, Ryotaro;Tsunoda, Takuya;Ishikawa, Fumihiro;Shibanuma, Motoko;Sasaki, Yasutsuna. And the article was included in Cancer Chemotherapy and Pharmacology in 2019.HPLC of Formula: 117976-90-6 The following contents are mentioned in the article:
Purpose: Several retrospective studies have shown that the antitumor efficacy of capecitabine-containing chemotherapy decreases when co-administered with a proton pump inhibitor (PPI). Although a reduction in capecitabine absorption by PPIs was proposed as the underlying mechanism, the effects of PPIs on capecitabine pharmacokinetics remain unclear. We prospectively examined the effects of rabeprazole on the pharmacokinetics of capecitabine and its metabolites. Methods: We enrolled patients administered adjuvant capecitabine plus oxaliplatin (CapeOX) for postoperative colorectal cancer (CRC) patients and metastatic CRC patients receiving CapeOX with/without bevacizumab. Patients receiving a PPI before registration were allocated to the rabeprazole group, and the PPI was changed to rabeprazole (20 mg/day) at least 1 wk before the initiation of capecitabine treatment. On day 1, oral capecitabine (1000 mg/m2) was administered 1 h after rabeprazole intake. Oxaliplatin (and bevacizumab) administration on day 1 was shifted to day 2 for pharmacokinetic anal. of the first capecitabine dose. Plasma concentrations of capecitabine, 5-deoxy-5-fluorocytidine, 5-deoxy-5-fluorouridine, and 5-fluorouracil were analyzed by high-performance liquid chromatog. Effects of rabeprazole on inhibition of cell proliferation by each capecitabine metabolite were examined with colon cancer cells (COLO205 and HCT116). Results: Five and 9 patients enrolled between Sept. 2017 and July 2018 were allocated to rabeprazole and control groups, resp. No significant effects of rabeprazole on area under the plasma concentration-time curve divided by capecitabine dose for capecitabine and its three metabolites were observed Rabeprazole did not affect the proliferation inhibition of colon cancer cells by the resp. capecitabine metabolites. Conclusion: Rabeprazole does not affect capecitabine pharmacokinetics. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6HPLC of Formula: 117976-90-6).
Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.HPLC of Formula: 117976-90-6
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem